<DOC>
	<DOCNO>NCT01420523</DOCNO>
	<brief_summary>Evaluation antiretroviral therapy combine Raltegravir Maraviroc patient virological success , present clinical lipohypertrophy .</brief_summary>
	<brief_title>Evaluation Raltegravir Plus Maraviroc Therapy Controlled HIV Patients Presenting With Lipohypertrophy</brief_title>
	<detailed_description>Assess ability maintain plasma HIV viral load threshold need detection ( &lt; 50 copies/mL ) 24 week raltegravir/maraviroc therapy without NRTIs PIs , patient virological success present clinical lipohypertrophy .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Patients infect HIV1 type B CRF02 . ≥ 18 year old Patients receive antiretroviral therapy least 5 year , whose treatment stable least 6 month . Patients whose plasma viral load undetectable ( 200 copies/mL ) last 24 month , &lt; 50 copies/mL least 12 month . Patients R5* tropic virus , determine DNA CD4 nadir ≥ 100/mm3 Patients present clinical lipohypertrophy recognize doctor , define increased volume abdominal and/or thoracic and/or cervical area ( buffalo hump ) . Patients never treat raltegravir . Patients never treat maraviroc . Efficient contraception woman Free inform write consent , sign patient investigator . Patients health insurance . * To increase certainty select patient R5 virus , HIV1 tropism determine genotype method interpret Geno2pheno [ coreceptor ] algorithm false positive rate threshold X4 virus 20 % , rather usual 10 % . X4 , X4/5 undetermined tropism HIV virus . HIV2 coinfection HIV1/HIV2 . Chronic viral hepatitis B . Chronic viral hepatitis C require specific treatment first 24 week . Treatment growth hormone . Hypolipemic diabetes treatment , begin within last 3 month . Pregnant breastfeed woman . Haemoglobin &lt; 7g/dl , neutrophil &lt; 500/mm3 , platelet &lt; 50 000/mm3 , creatinine clearance &lt; 50 mL/min , alkaline phosphatase , ASAT , ALAT bilirubin ≥ 3 time upper limit normal range ( N ) . Antiretroviral treatment associate enzymatic inducer . Chronic alcohol consumption . Subjects `` sauvegarde de justice '' ( judicial protection due temporarily slightly diminish mental physical faculty ) , legal guardianship . Subjects participate another clinical trial evaluate different therapy include exclusion period still force screen phase .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>HIV</keyword>
	<keyword>Lipohypertrophy</keyword>
</DOC>